Stockscreener 앱 받기
0.84
0.84%
-0.0071
시간 외 거래:
.88
0.04
+4.76%
전일 마감가:
$0.8471
열려 있는:
$0.86
하루 거래량:
618.73K
Relative Volume:
0.50
시가총액:
$65.74M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-42.00
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
-4.56%
1개월 성능:
-25.66%
6개월 성능:
-41.67%
1년 성능:
-48.47%
1일 변동 폭
$0.82
$0.86
1주일 범위
$0.79
$0.9178
52주 변동 폭
$0.79
$5.85
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
0.84 | 65.74M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Short Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Drops By 13.4% - MarketBeat
Jane Street Group LLC Decreases Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX stock plunges to 52-week low, touches $0.83 By Investing.com - Investing.com Canada
CytomX stock plunges to 52-week low, touches $0.83 - Investing.com India
Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.77 - MarketBeat
Bay Area biotech firm CytomX, once worth $2.3 billion, lays off 40% of staff - MSN
Bay Area biotech firm once worth $2.3 billion lays off 40% of staff - SFGATE
Geode Capital Management LLC Has $948,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX Therapeutics’ (CTMX) Neutral Rating Reiterated at HC Wainwright - Defense World
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - News & Insights
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - Nasdaq
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CytomX Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
CytomX falls after portfolio shakeup, job cuts - MSN
CytomX Therapeutics' SWOT analysis: oncology biotech's stock faces pivotal year - Investing.com
CytomX stock falls on portfolio shakeup (CTMX:NASDAQ) - Seeking Alpha
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy - Yahoo Finance
CytomX to Cut 40% of Staff as It Updates Pipeline Priorities - BioSpace
CytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC Wainwright - MarketBeat
CytomX refocuses on key cancer drug, extends cash runway - Investing.com India
CTMXCytomX Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
CytomX announces restructuring, staff cuts to extend cash runway - Investing.com
CytomX announces restructuring, staff cuts to extend cash runway By Investing.com - Investing.com South Africa
CytomX refocuses on key cancer drug, extends cash runway By Investing.com - Investing.com Canada
Peninsula biotech to lay off 40% of workforce as it restructures - The Business Journals
CytomX Therapeutics to Cut 40% of Workforce - MarketWatch
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update - The Manila Times
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA - Zacks Investment Research
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 26.2% in December - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Average Price Target from Analysts - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Position Raised by Fmr LLC - Defense World
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine - MSN
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS - MSN
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry - Simply Wall St
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
CytomX Therapeutics' SWOT analysis: biotech stock's solid tumor focus By Investing.com - Investing.com Canada
Janus Henderson Group PLC Trims Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - MarketBeat
Recent uptick might appease CytomX Therapeutics, Inc. (NASDAQ:CTMX) institutional owners after losing 21% over the past year - Simply Wall St
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in November - MarketBeat
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Brokerages - Defense World
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Consensus Price Target from Analysts - MarketBeat
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround - Yahoo Finance
CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com India
Biotechnology Value Fund L P Increases Stake in CytomX Therapeutics Inc - GuruFocus.com
TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):